Luis Antonio Díaz, MD @LuisAntonioDiaz Twitter Profile

Luis Antonio Díaz, MD

@LuisAntonioDiaz

Researcher at the @MASLDResearch @UCSD_GI and Gastroenterologist and Assistant Professor at @FacMedicinaUC

716Posts 842Followers 745Following

Similar User

@juanpabloarab

@alehlatam

@ReibergerThomas

@sebas_marciano

@MMendizabalMD

@VirginiaHdezGea

@ADNARVAEZ22

@GCastro_NarroMD

@salvatore_piano

@ruben_hernaez

@MarcoArreseMD

@c_labenz

@docberza

@JosPresa3

@gui_cancado

Luis Antonio Díaz, MD Reposted

Sebastian Marciano

@sebas_marciano

3 h

📢 Live from #TLM2024 Important study by P. Huerta & @LuisAntonioDiaz ➡️ACLF III is a determinant of death in patients with alcohol-related hepatitis. ➡️Early referral of these pts for LT is crucial @AASLDtweets @alehlatam

Luis Antonio Díaz, MD Reposted

Rohit Loomba

@DrLoomba

17 Nov

Work locally impact globally- Such an honor and privilege to host colleagues from more than 30 countries for a packed full house @UCSD_GI reception at #TLM2024 gratitude 🙏 to all who attended @pattymaysent !!

Bernd Schnabl

@Bernd_Schnabl

17 Nov

Schnabl lab members are the last one to leave the party. So proud of this incredible team. Thank you @DrLoomba for organizing a fantastic UCSD reception at #TLM24 @CristiLlorente @CynthiaLHsu @UCSD_GI @SDDRC

Luis Antonio Díaz, MD Reposted

Jeffrey V. Lazarus

@JVLazarus

17 Nov

Dr @SagiZelber presenting our work "Food inequity and insecurity and MASLD: burden, challenges, and interventions" nature.com/articles/s4157… @NatRevGastroHep #TLM24

Luis Antonio Díaz, MD

@LuisAntonioDiaz

16 Nov

We still have a lot of things to do in the MetALD clinical trials design! Great talk @juanpabloarab ! @VCU @VCU_Liver @MarcoArreseMD @ArunJSanyalVCU @AASLDtweets

Luis Antonio Díaz, MD Reposted

David Marti Aguado

@Dmarti_aguado

16 Nov

Clinical trial design for MetALD 🤔 @juanpabloarab shows us how we will need to account for common mechanistic pathways 🍻🍔 More questions than answers, great opportunities for research 👩‍🔬 #TLM2024 @AASLDtweets

Luis Antonio Díaz, MD

@LuisAntonioDiaz

16 Nov

Thank you @AASLDtweets for invite me to discuss about screening in SLD at the Liver Meeting 2024, it was an honor to participate! Great session with @norahterrault and @juanpabloarab #LiverTwitter @MASLDResearch @UCSD_GI

Qasim Khan, MBBS, MS, FRCPC

@mqkMD

16 Nov

@LuisAntonioDiaz discusses screening and risk stratification of MASLD-MetALD-ALD 🏃‍♀️🍻: - Many NITs / Elastography techniques! - 🪜-wise approach may need tweaking to ensure👍🏼 performance in hi-risk pop. eg Hispanics - Stratifying can modulate lifestyle 🍔🍺@AASLDtweets #TLM2024

Luis Antonio Díaz, MD Reposted

Juan Pablo (JP) Arab, MD 

@juanpabloarab

16 Nov

Starting our Joint ALD/MASLD program! Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and MetALD: Beyond the Nomenclature, Part 1 Room: Convention Center: Ballroom 6B Full house! @AlinaAllenMD @norahterrault @LuisAntonioDiaz…

Luis Antonio Díaz, MD Reposted

Rohit Loomba

@DrLoomba

14 Nov

Grateful to have such an inspiring meeting and appreciate the intellect on this panel @MetALDconf — great group to push drug development and novel biomarkers in metALD !!! @LuisAntonioDiaz @AjmeraVeeral @VWSWong @f_tavaglione @QAnstee @AASLDtweets

MetALD Conference

@MetALDconf

14 Nov

Thank you to the MetALD Conference faculty for an excellent day of lectures and insightful learning!

Luis Antonio Díaz, MD Reposted

Anand V Kulkarni

@AnandVKulkarni2

15 Nov

Beautiful talk by ⁦@ponnivp⁩ on managing AUD. Trials on MASH cirrhosis- ⁦@NoureddinMD⁩ Does alcohol intake increase post bariatric surgery? ⁦@rabataller⁩ ⁦@LuisAntonioDiaz⁩ @juanpabloarab⁩ #livertwitter #TLM24

Luis Antonio Díaz, MD Reposted

Maja Thiele

@MajaThiele

15 Nov

Thanks Luis! Happy you enjoyed. So many great talks and discussions today - I have three pages packed with notes to digest. Best way to start #TLM2024

Luis Antonio Díaz, MD

@LuisAntonioDiaz

14 Nov

How to innovate in MetALD clinical trials? @DrLoomba provided relevant considerations for security and endpoints. NITs biomarkers may play a role in early phase studies! @MASLDResearch @f_tavaglione @DrMaralMD @AjmeraVeeral @MonicaTincopa @UCSD_GI #LiverTwitter @MetALDconf

Luis Antonio Díaz, MD Reposted

Rohit Loomba

@DrLoomba

14 Nov

Great panel of experts ⁦@MetALDconf⁩ - grateful for everyone’s insightful engagement!! ⁦@NIAAAnews⁩ ⁦@US_FDA⁩ ⁦@AASLDtweets⁩ ⁦@AmerGastroAssn⁩ ⁦@AmCollegeGastro⁩ Thanks 🙏 to everyone ⁦⁦@VWSWong⁩ ⁦@QAnstee⁩ ⁦@marurinella⁩

Luis Antonio Díaz, MD Reposted

MetALD Conference

@MetALDconf

14 Nov

Session One Panel Discussion at the MetALD Conference!

Luis Antonio Díaz, MD

@LuisAntonioDiaz

14 Nov

I am thrilled for the recent evidence in PEth testing to better classify SLD subtypes. Great presentation by @f_tavaglione at the @MetALDconf ! @DrLoomba @f_tavaglione @AjmeraVeeral @DrMaralMD @MASLDResearch @UCSDHealth @UCSD_GI #LiverTwitter

Luis Antonio Díaz, MD

@LuisAntonioDiaz

14 Nov

Pros and cons of current NITs in MetALD. Inflammation, excess weight, alcohol use and low specificity are the main caveats of NITs. Fantastic talk from @MajaThiele at the @MetALDconf ! #LiverTwitter @DrLoomba @AleksanderKrag @EASLedu @EASLnews @MASLDResearch

Luis Antonio Díaz, MD Reposted

Rohit Loomba

@DrLoomba

14 Nov

So proud of you @LuisAntonioDiaz - such a wonderful job in helping organize @MetALDconf and start the Delphi process on consensus @NatRevGastroHep @heykatray